Important safety information on methotrexate dosage
21.04.2009
The Agency for Medicinal Products and Medical Devices sent a letter to healthcare professionals with important safety information on methotrexate dosage for oral use when indicated for treatment of psoriasis and rheumatoid arthritis.
The letter contains important information on correct methotrexate dosage in order to avoid inadvertent overdose caused by medication error or by incorrect use of the once-weekly dose as daily dose.
The oral form of methotrexate is not approved for marketing in the Republic of Croatia, but it is available to Croatian patients through import.
The text of the letter can be found below:
"Important safety information on methotrexate dosage-Croatian document"
